The 67th Annual Meeting of the American Society for Radiation Oncology (ASTRO25) takes place in San Francisco from September 27 to October 1, 2025, at the Moscone Center.
This leading event brings together radiation oncologists, researchers, and industry experts worldwide. Designed for radiation oncologists, medical physicists, radiation therapists, and oncology professionals, ASTRO 2025 offers a comprehensive program focused on rediscovering radiation medicine, exploring new clinical indications, and advancing radiation therapy research and patient care. The meeting features cutting-edge scientific sessions, educational presentations, and exhibits showcasing the latest innovations in radiation oncology.
Many physicians and organizations have shared posts from Day 1 of ASTRO25.
“And the plot thickens for short-course RT in rectal cancer!
72% cCR and 57% 2-year TME free survival via 4 cycles FOLFOX/CAPOX –> 25-30Gy/5 fraction RT (short course with optional boost).
Congrats Hyun Kim and looking forward to study details.”
“We made it to ASTRO25 Continuing the tradition of brining a kiddo to each conference.
Opportunity to have one on one time plus show them why I love what I do.”
“Excited to be presenting at ASTRO25 in San Francisco!
Representing Mass General Cancer Center with two talks:
- Chordoma analysis from PROG 85-26
- Growth outcomes after vertebral body sparing proton CSI in pediatric CNS tumors
Both abstracts will also be discussed in the Science Highlights sessions (Sarcoma and Pediatric) on Sunday morning.
Looking forward to reconnecting and meeting many of you soon in SF!”
“Honored to receive the Basic/Translational Science Abstract Award at ASTRO25.
Excited to present our work: ‘Unveiling Early Radiation Effects on the Hippocampus: ADC Dynamics Reveal Microstructural Changes during Therapy’.
Grateful to my mentors and MD Anderson Cancer Center team.”
“Relaxing the long V5 constraint can lower heart and lung doses, especially in patients with higher baseline heart exposure.
Current V5 rules may be too strict, and careful adjustment could give real benefit to OARs.”
“An important study presented at ASTRO25 demonstrates the deleterious effects of using V5 lung constraints for thoracic radiation therapy treatment planning, and hopefully puts an end to this sad era in our field when some of us thought it mattered .”
“From skepticism to evidence
- 50% improved >5 VAS points
- 40% cut analgesics
- 0 toxicities
Low-dose RT works for painful musculoskeletical disorders. Period.
“Thank you The Association of Residents in Radiation Oncology (ARRO) for planning today’s brachytherapy workshop!
It was a great learning opportunity”
Harvard Radiation Oncology Program
“Congratulations to our very own Jake Hogan already making waves in ASTRO25 as recipient of the 2025 ARRO Health Care Access Publication Award for his study, ‘Radiotherapy Utilization in Traditional Medicare and Medicare Advantage’ published in JAMA Network Open.
Amazing work!”
“Psuedoprogression Radiation Necrosis vs progression new imaging techniques treating Rad Nec using Boswellia CNS PRO session, ASTRO25.”
“Sham-controlled RCT on LDRT for OA!
That 42% reported pain improvement in sham arm emphasizes importance of conducting sham-controlled RCTs for interventions w symptom/pain endpoints – an uncontrolled RCT would have dramatically overstated efficacy (70% with 3Gy).”
“Moffitt Cancer Center is at ASTRO25!
We are thrilled to be joining radiation oncology experts from across the world this week to collaborate and share the latest science.
To see what our experts are presenting, visit website and follow Moffitt Cancer Center for live updates!”
“RLT in Metastatic Prostate Cancer moving Pluvicto earlier in the disease course and predicting response based on PSMA SUV and PSMA tumor burden.”
“City of Hope researchers are taking the stage at ASTRO25 to present bold, data-driven breakthroughs in radiation oncology.”
Association of Residents in Radiation Oncology (ARRO)
“Congratulations to all of our very deserving award recipients who were recognized today at ARRO Day here at ASTRO25.
Some of those able to join us today are pictured below.”
“Huge congratulations to the investigators for completing the first-ever RCT of proton vs photon RT in breast cancer!
At 6 months: quality of life excellent in both arms.
Awaiting future LRC and cardiac data. Excited to hear details from Shannon M MacDonald plenary!”
“The University of Michigan connection is strong among the SCAROP group at ASTRO25.
Great to see the group come together and proud of the Michigan legacy. Missing Reshma Jagsi though.
You’re here in spirit!
“At ASTRO25 there are two entire sessions dedicated to radiotherapy in kidney cancer!
All-star cast, please pop by on Monday and/or Tuesday to learn something interesting about radiation oncology!”
“Dr. Chelsea Pinnix leads an education session at ASTRO25 on toxicity reduction efforts with radiation therapy for patients with indolent lymphoma.”
“Looking forward to Clinical Trial session at ASTRO25.
Schedule:
- 01:00 PM – 01:10 PM PT
Speaker: Daniel Spratt, MD
A Double-Blinded Placebo-Controlled Biomarker Stratified Randomized Trial of Apalutamide (APA) and Radiotherapy for Recurrent Prostate Cancer (NRG GU006, BALANCE trial) - 01:10 PM – 01:20 PM PT
Speaker: Amar Kishan, MD, PhD
177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer; Primary Endpoint Analysis of the Phase II LUNAR Randomized Trial - 01:20 PM – 01:30 PM PT
Speaker: Mack Roach, MD, PhD, FASTRO
Androgen Deprivation Therapy (ADT) and High Dose Definitive Radiotherapy (RT) +/- Whole Pelvic RT in Patients with Unfavorable Intermediate or Favorable High-Risk Prostate Cancer: Early Results of a Phase III Randomized Controlled Trial - 01:30 PM – 01:40 PM PT
Discussant: Karen Hoffman, MD, FASTRO - 01:40 PM – 01:50 PM PT
Speaker: Jarad Martin, MB, ChB, PhD
Toxicities and Quality of Life Following Observation or Radiation Therapy for Dupuytren’s Disease in the International DEPART Randomized Trial - 01:50 PM – 02:00 PM PT
Speaker: Byoung Hyuck Kim, MD, PhD
Clinical Effectiveness of Single Course Low-Dose Radiation Therapy in Knee Osteoarthritis: Short-term Results from the Randomized, Sham-Controlled Trial - 02:00 PM – 02:10 PM PT
Discussant: Gopal Bajaj, MD, MBA, FASTRO - -02:10 PM – 02:20 PM PT
Speaker: Christopher Kelse, MD, FASTRO
Decreasing the Dose of Consolidation Radiation Therapy in DLBCL/HGBL: A Phase II Trial by the International Lymphoma Radiation Oncology Group - 02:20 PM – 02:30 PM PT
Speaker: Feng Liu, MD
Efficacy of Hypofractionated Stereotactic Radiotherapy with Different Dose Fractionation Regimens Combined with Concurrent Bevacizumab in Recurrent High-Grade Gliomas: A Randomized Controlled Trial
Don’t miss these insightful discussions on the latest advancements in cancer treatment!”
My first ASTRO25 selfie with the amazing ASTRO cancer survivor, radiation advocate and ASTRO PR Director Jeff White!
Thanks for your amazing work to advance ASTRO’s mission.”
“Looking forward to learning ‘all the things’ at my first ASTRO annual meeting.
Started off on the right note when the woman at registration said, ‘Thank you for your advocacy. Go patient advocates!’ and literally punched the air!”
“Emily caught up with ASTRO Fellow Bobby Koneru at ASTRO25 to discuss how, in addition to treating cancer, he’s using LDRT to improve quality of life for patients with conditions like osteoarthritis.
He believes tendinopathies such as plantar fasciitis and Achilles tendinitis are an area that hasn’t received enough attention and expects more clinicians will start taking notice.
Are you using radiotherapy to treat non-oncologic conditions?
Watch the video attached to this post.
More from ASTRO25 on OncoDaily.
